NCT04705103

Brief Summary

Uveitis is a recurrent inflammation of the eye that can lead to vision loss with various and complicated etiologies. There are many difficulties in uveitis management due to the requirement of long-term monitoring and treatment. This study intends to establish a longitudinal cohort of uveitis patients to colloect multimodal clinical data including visual acuity, intraocular pressure, anterior segment photography, fundus photography, fluoroscopy and other ophthalmic examinations, and final diagnosis in order to use artificial intelligence and deep learning technology to extract ocular features, explore the association with the progression and prognosis of uveitis and finally establish a disease management model for uveitis.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
450

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2021

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 8, 2021

Completed
2 days until next milestone

Study Start

First participant enrolled

January 10, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 12, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

January 12, 2021

Status Verified

January 1, 2021

Enrollment Period

1.9 years

First QC Date

January 8, 2021

Last Update Submit

January 8, 2021

Conditions

Uveitis

Outcome Measures

Primary Outcomes (1)

  • uveitis progression

    uveitis progression is divided into remission, relapse, or initial

    up to 1 month

Study Arms (3)

initial

relapse

inactive

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

1. Initial stage of uveitis: The first episode of uveitis without treatment; 2. Remission of uveitis: Uveitis caused by various reasons in the stable disease period of more than 3 months without treatment; 3. Relapse of uveitis: After discontinuation of uveitis treatment, the disease stabilized for more than 3 months.

You may qualify if:

  • Participants who were diagnosed as uveitis, including the initial stage or relapse, or remission of uveitis.

You may not qualify if:

  • Participants who cannnot cooperate with ocualr examination.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Uveitis

Condition Hierarchy (Ancestors)

Uveal DiseasesEye Diseases

Central Study Contacts

Haotian Lin, M.D.,Ph.D

CONTACT

13802793086gddlht@aliyun.com

shuyi Zhang, M.D.

CONTACT

15622177115shuyi_z@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 8, 2021

First Posted

January 12, 2021

Study Start

January 10, 2021

Primary Completion

November 30, 2022

Study Completion

December 30, 2022

Last Updated

January 12, 2021

Record last verified: 2021-01